A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD

被引:60
作者
Archer, SL
Mike, D
Crow, J
Long, W
Weir, EK
机构
[1] UNIV MINNESOTA,MINNEAPOLIS,MN 55455
[2] BURROUGHS WELLCOME CO,RES TRIANGLE PK,NC 27709
[3] UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC
关键词
cor pulmonale; prostacyclin; pulmonary hypertension; systemic O-2 transport;
D O I
10.1378/chest.109.3.750
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Although patients with COPD often have elevated pulmonary artery pressures (PAP) and pulmonary vascular resistance (PVR), it is uncertain whether treatment of this pulmonary hypertension is beneficial. We evaluated the extent of pulmonary hypertension in 16 patients with severe COPD complicated by acute respiratory failure and pulmonary hypertension. We assessed the hypothesis that the vasodilator prostacyclin (PGI(2)) would reduce PVR and improve systemic O-2 transport. Patients with a COPD exacerbation requiring mechanical ventilation, and mean PAP greater than 30 mm Hg, were randomized to receive PGI(2) or placebo, in addition to conventional therapy. Randomization to PGI(2) or placebo therapy occurred 1 to 12 h after intubation, while the patient was mechanically ventilated. An optimal PGI(2) dose (2 to 12 ng/kg/min, IV) was established in an initial dose-ranging study and then this dose was infused continuously for 48 h, PGI(2) initially reduced PVR, but this effect dissipated within 24 h, indicating the development of tachyphylaxis. Tolerance to the adverse effects of PGI(2) (tachycardia, hypotension, flushing, and headache) also developed over time. PGI(2) treatment was associated with a significant fall in PaO2 but no increase in systemic oxygen transport. PGI(2) proved to be a nonselective vasodilator that caused mild hypoxemia. Despite acute respiratory failure, pulmonary hypertension is mild in patients with severe COPD receiving mechanical ventilation and IV PGI(2) is not beneficial in such patients.
引用
收藏
页码:750 / 755
页数:6
相关论文
共 20 条
  • [1] FREE-SURFACE VELOCITY-MEASUREMENT OF SHOCK-COMPRESSED ALUMINA POWDER COMPACT USING A FABRY-PEROT-INTERFEROMETER
    TANIGUCHI, T
    YASUO, H
    KONDO, K
    SAWAOKA, AB
    [J]. JOURNAL OF APPLIED PHYSICS, 1989, 66 (04) : 1662 - 1666
  • [2] AN IMBALANCE BETWEEN THE EXCRETION OF THROMBOXANE AND PROSTACYCLIN METABOLITES IN PULMONARY-HYPERTENSION
    CHRISTMAN, BW
    MCPHERSON, CD
    NEWMAN, JH
    KING, GA
    BERNARD, GR
    GROVES, BM
    LOYD, JE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (02) : 70 - 75
  • [3] VENTILATION-PERFUSION AND GAS-EXCHANGE EFFECTS OF SODIUM-NITROPRUSSIDE IN DOGS WITH NORMAL AND EDEMATOUS LUNGS
    COLLEY, PS
    CHENEY, FW
    HLASTALA, MP
    [J]. ANESTHESIOLOGY, 1979, 50 (06) : 489 - 495
  • [4] COTTRELL MB, 1991, P SOC EXP BIOL MED, V197, P261
  • [5] INHALED NITRIC-OXIDE - A SELECTIVE PULMONARY VASODILATOR REVERSING HYPOXIC PULMONARY VASOCONSTRICTION
    FROSTELL, C
    FRATACCI, MD
    WAIN, JC
    JONES, R
    ZAPOL, WM
    [J]. CIRCULATION, 1991, 83 (06) : 2038 - 2047
  • [6] INHALED NITRIC-OXIDE SELECTIVELY REVERSES HUMAN HYPOXIC PULMONARY VASOCONSTRICTION WITHOUT CAUSING SYSTEMIC VASODILATION
    FROSTELL, CG
    BLOMQVIST, H
    HEDENSTIERNA, G
    LUNDBERG, J
    ZAPOL, WM
    [J]. ANESTHESIOLOGY, 1993, 78 (03) : 427 - 435
  • [7] GROSSMAN W, 1991, CARDIAC CATHETERIZAT, P105
  • [8] A COMPARISON OF THE ACUTE HEMODYNAMIC-EFFECTS OF PROSTACYCLIN AND HYDRALAZINE IN PRIMARY PULMONARY-HYPERTENSION
    GROVES, BM
    RUBIN, LJ
    FROSOLONO, MF
    CATO, AE
    REEVES, JT
    [J]. AMERICAN HEART JOURNAL, 1985, 110 (06) : 1200 - 1204
  • [9] PULMONARY VASODILATION WITH PROSTACYCLIN IN PRIMARY AND SECONDARY PULMONARY-HYPERTENSION
    JONES, K
    HIGENBOTTAM, T
    WALLWORK, J
    [J]. CHEST, 1989, 96 (04) : 784 - 789
  • [10] LANGDON JR, 1977, EXP HEMATOL, V5, P191